JP2004529207A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529207A5
JP2004529207A5 JP2003504987A JP2003504987A JP2004529207A5 JP 2004529207 A5 JP2004529207 A5 JP 2004529207A5 JP 2003504987 A JP2003504987 A JP 2003504987A JP 2003504987 A JP2003504987 A JP 2003504987A JP 2004529207 A5 JP2004529207 A5 JP 2004529207A5
Authority
JP
Japan
Prior art keywords
lhrh antagonist
methyl
medicines
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003504987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/004677 external-priority patent/WO2002102401A1/en
Publication of JP2004529207A publication Critical patent/JP2004529207A/ja
Publication of JP2004529207A5 publication Critical patent/JP2004529207A5/ja
Withdrawn legal-status Critical Current

Links

JP2003504987A 2001-04-30 2002-04-27 Lhrhアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療 Withdrawn JP2004529207A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (2)

Publication Number Publication Date
JP2004529207A JP2004529207A (ja) 2004-09-24
JP2004529207A5 true JP2004529207A5 (https=) 2005-12-22

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003504987A Withdrawn JP2004529207A (ja) 2001-04-30 2002-04-27 Lhrhアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療

Country Status (27)

Country Link
US (1) US7288517B2 (https=)
EP (1) EP1392348B1 (https=)
JP (1) JP2004529207A (https=)
KR (1) KR20040000446A (https=)
CN (1) CN1317030C (https=)
AT (1) ATE400287T1 (https=)
AU (1) AU2002310788B2 (https=)
BG (1) BG108339A (https=)
BR (1) BR0209290A (https=)
CA (1) CA2444876A1 (https=)
CZ (1) CZ20033167A3 (https=)
DE (1) DE60227507D1 (https=)
DK (1) DK1392348T3 (https=)
ES (1) ES2307760T3 (https=)
HU (1) HUP0400067A2 (https=)
IL (1) IL156777A0 (https=)
MX (1) MXPA03008666A (https=)
NO (1) NO20034322L (https=)
NZ (1) NZ544417A (https=)
PL (1) PL362319A1 (https=)
PT (1) PT1392348E (https=)
RU (1) RU2319501C2 (https=)
SI (1) SI1392348T1 (https=)
SK (1) SK14512003A3 (https=)
UA (1) UA80679C2 (https=)
WO (1) WO2002102401A1 (https=)
ZA (1) ZA200305326B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6960591B2 (en) * 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US7709519B2 (en) * 2004-06-04 2010-05-04 Astellas Pharma Inc. Benzimidazolylidene propane-1,3 dione derivative or salt thereof
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
CN101573352A (zh) * 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
KR20100056508A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 폐렴 연쇄상 구균 감염의 치료를 위한 bfgf 1-24 및 임의의 (arg 8)바소프레신의 용도
WO2009033730A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratoires Ag Peptide gxgrgdspca as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
AU710926B2 (en) 1996-05-20 1999-09-30 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
MXPA02003614A (es) * 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
US20030134863A1 (en) 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
US6960591B2 (en) * 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative

Similar Documents

Publication Publication Date Title
JP2004529207A5 (https=)
JP2005515966A5 (https=)
AP2001002288A0 (en) Methods for treatment of sickle cell anemia.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
HK19395A (en) Film-coated solid dosage form of anti-migraine drug
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
HUP0402230A2 (hu) Többszörös bevonattal ellátott gyógyszer dózisforma
CN1159754A (zh) 改进的含有布洛芬和可待因的药物配方
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
RU2003134949A (ru) Способ лечения деменции и нейродегенеративных заболеваний и применение в нем качестве лекарственного средства промежуточных доз антагонистов lhrh
JP2006515299A5 (https=)
CA2508611A1 (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
US20020037930A1 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
JP2002540148A5 (https=)
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
WO2002067905A1 (en) A sustained release pharmaceutical formulation
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
JP2003523385A5 (https=)
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
JP4983750B2 (ja) 経口投与用製剤